Our objective is to improve the overall outlook for patients with malignant diseases. This objective includes not only efforts to prolong the survival of such patients, but also to improve the quality of their lives. We recognize that relatively speaking, at any one institution, these diseases are annually encountered in numbers too small to allow controlled clinical trials within a reasonable time frame. Our participation as a member institution of the Cancer and Leukemia Group B (CALGB) enables us to surmount this difficulty. We have been a member institution of the CALGB for 21 years. We have established a functioning multidisciplinary team-effort for planning and actual dispensing of treatment of patients with cancer. Appropriate specialists from medical oncology, surgery, radiation therapy, pathology, psychiatry, social service and nursing department are fully involved. Consistent with our approach to the patient as a whole rather than only to the cancer site, our studies lay particular stress on predictive testing both in vivo (staging) and in vitro, to determine the most effective therapy. By involving all medical and paraprofessional staff in such controlled clinical trials, we encourage the investigational and research traits in our faculty. In many respects, the development of our efforts has paralled the development of CALGB. During the period of study in this grant application we will strive towards increasing accrual of patients on CALGB studies and also towards developing new protocols originating from LIJ for group-wide trials. Senior members of staff from LIJ and affiliated institutions have provided leadership roles to the entire group in areas as diverse as study design and chairmanship of major leukemia protocols to Constitution & By-Laws and Ethics and Peer Review committees. Our institution has a well established tradition of conviction and dedication to CALGB activities in efforts towards control of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA011028-21
Application #
3555948
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-04-01
Project End
1993-03-31
Budget Start
1988-04-01
Budget End
1989-03-31
Support Year
21
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8
Smith, S M; Johnson, J; Cheson, B D et al. (2009) Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-17
Stinchcombe, Thomas E; Hodgson, Lydia; Herndon 2nd, James E et al. (2009) Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:1117-25
Blanke, Charles D; Rankin, Cathryn; Demetri, George D et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32
Bogart, Jeffrey A; Watson, Dorothy; McClay, Edward F et al. (2008) Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer 62:92-8
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2008) Wilms'tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-602
Chan, Jennifer A; Meyerhardt, Jeffrey A; Niedzwiecki, Donna et al. (2008) Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA 299:2515-23
Miller, Antonius A; Murry, Daryl J; Owzar, Kouros et al. (2007) Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25:3055-60
Vokes, Everett E; Herndon 2nd, James E; Kelley, Michael J et al. (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-704

Showing the most recent 10 out of 36 publications